| |
|
|
|
|
|
|
|||
|
LJ Levitt
We investigated the mechanism for isolated agranulocytosis and marrow pure
white cell aplasia in an elderly man receiving 0.5 to 1.0 g per day of
chlorpropamide (Chl) without other toxic drug exposure or overt systemic
illness. Patient marrow revealed an absence of recognizable granulocytic
precursors; megakaryocytes and erythroid precursors were normal. The WBC
count was 1800/mm3 on admission with only 2% neutrophils; the absolute
neutrophil count first exceeded 500/mm3 on the 17th day following cessation
of Chl. A serum Chl level on admission was 100 micrograms/mL (acute phase,
AP); no Chl was detected in serum (convalescent phase, CP) assessed on the
22nd hospital day. Antineutrophil antibodies were not detected, and T cell
depletion failed to augment patient in vitro granulopoiesis. Patient AP
serum produced potent complement-mediated inhibition (87% +/- 7%) of
autologous granulocyte progenitors (CFU-GM) with minimal inhibition of
erythroid (11% +/- 5%) or multipotent (5% +/- 4%) progenitor cells.
Selective inhibition by patient AP serum of CFU-GM (74% +/- 11%) was also
seen against two allogeneic marrows. Patient CP serum no longer inhibited
(6% +/- 4%) autologous CFU-GM. Addition of Chl (5 to 120 micrograms/mL) to
CP serum but not to control serum resulted in potent drug
concentration-dependent complement-mediated inhibition of autologous and
allogeneic CFU-GM. Inhibition of CFU-GM in the presence of Chl was no
longer demonstrable following immunoabsorbent removal of IgG from patient
serum. Patient serum in the presence of Chl had limited activity against
morphologically recognizable marrow granulocytic precursors in a
microimmunofluorescence assay. These results are most consistent with the
development of Chl-dependent, selective antibody-mediated immune inhibition
of granulopoiesis.
This article has been cited by other articles:
| |||||||||||
| Copyright © 1987 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||